RT Journal Article SR Electronic T1 Glycemic variability and cardiovascular disease in patients with type 2 diabetes JF BMJ Open Diabetes Research & Care JO BMJ Open Diab Res Care FD American Diabetes Association SP e002032 DO 10.1136/bmjdrc-2020-002032 VO 9 IS 1 A1 Marcela Martinez A1 Jimena Santamarina A1 Adrian Pavesi A1 Carla Musso A1 Guillermo E Umpierrez YR 2021 UL http://drc.bmj.com/content/9/1/e002032.abstract AB Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes.